Back to mobile site

More on ABCL

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-50.0% Growth)
- Ratings (9.2 Score)
- Holders

Upcoming Events

- Earnings (11/6/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

AbCellera (NQ:ABCL)
Delayed: 9.34 +2.41 (34.78%)
Prev. Close $6.93  
Open$8.76 
52 Wk High$ 
52 Wk Low$ 
Day High$10.01 
Day Low$8.40 
P/E N/A  
EPS$ 
Volume46,022,181 

Friends, Peers and Foes (?): JAZZ, VRTX, ABSI, CERT, DOCS (more...)

Aug 10, 2026 10:40 AM The Catalysts are Back: Socket Mobile Breaks Out while Biotechs Race Toward Major Milestones
Aug 10, 2026 09:10 AM AI Found an Influenza Target That Survives Viral Mutation
Aug 10, 2026 07:49 AM Form 8-K AbCellera Biologics Inc. For: Aug 10
Aug 10, 2026 07:00 AM AbCellera Phase 2 trial shows ABCL635 cuts hot flash frequency by 83%
Aug 10, 2026 07:00 AM AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profi
Aug 7, 2026 04:44 PM Form 8-K AbCellera Biologics Inc. For: Aug 07
Aug 7, 2026 04:30 PM AbCellera to release phase 2 trial data for menopause drug Aug. 10
Aug 7, 2026 04:30 PM AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
Aug 6, 2026 08:09 AM AbCellera Biologics (ABCL) PT Raised to $9 at Stifel
Aug 5, 2026 04:30 PM Form 10-Q AbCellera Biologics Inc. For: Jun 30
View All Articles

Entities mentioned with ABCL

View All Entities